“
“Purpose: Urinary tumor markers that help in
the early detection of bladder cancer promise a significant improvement in sensitivity, specificity and convenience over conventional, invasive diagnostic tests. We assessed the diagnostic efficacy of hyaluronidase (HYAL1) and survivin for early bladder cancer detection.
Materials BMS202 clinical trial and Methods: The study included 166 patients diagnosed with bladder carcinoma, 112 with benign bladder lesions and 100 healthy volunteers who served as controls. All underwent serological assessment of schistosomiasis antibody, urine cytology, and hyaluronidase (HYAL1) and survivin RNA estimation by qualitative and semiquantitative reverse transcriptase-polymerase chain reaction in urothelial cells from voided urine.
Results: Positivity rates of HYAL1 RNA and survivin RNA on qualitative reverse transcriptase-polymerase
chain reaction were significantly different among the 3 groups. Mean rank using semiquantitative method was increased in the malignant vs the other groups. The best cutoff for this website HYAL1 and survivin RNA was 0.25 each. Using these cutoffs HYAL1 and survivin RNA sensitivity was 91% and 75%, respectively, with absolute specificity. HYAL1 RNA detected all patients with stages 0 and I bladder cancer (p < 0.037). Urine cytology sensitivity improved when combined with hyaluronidase or survivin RNA on semiquantitative reverse transcriptase-polymerase chain reaction.
Conclusions: The detection of urinary HYAL1 and survivin RNA is a promising noninvasive test for bladder cancer early detection. HYAL1 RNA was more sensitive and specific than urine cytology. Semiquantitative reverse transcriptase-polymerase chain reaction is favored for its high sensitivity and specificity.”
“We conducted a systematic review of the neuroimaging literature examining cognition in old and young adults and quantified these findings in a series of meta-analyses using the activation likelihood estimation technique. In 80 independent samples, we assessed significant convergent and divergent patterns of brain activity across all studies; where task performance was equated or different between age groups; and in four specific cognitive domains (perception, memory encoding,
memory retrieval and executive function). Age differences across studies predominantly involved regions within the ‘task-positive network’ of the brain, a set of interconnected regions Volasertib in vitro engaged during a variety of externally driven cognitive tasks. Old adults engaged prefrontal regions more than young adults. When performance was equivalent, old adults engaged left prefrontal cortex; poorly performing old adults engaged right prefrontal cortex. Young adults engaged occipital regions more than old adults, particularly when performance was unequal and during perceptual tasks. No age-related differences were found in the parietal lobes. We discuss the reliable differences in brain activation with regards to current theories of neurocognitive aging. (C) 2010 Elsevier Ltd.